

AD _____

Award Number: W81XWH-09-1-0294

TITLE: Immunotherapy of Prostate Cancer With Genetically Enhanced Tumor-Specific T-Cell Precursors

PRINCIPAL INVESTIGATOR: Dr. Marcel van den Brink

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research
New York, NY 10021

REPORT DATE: June 2011

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-06-2011		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 JUN 2010 - 31 MAY 2011	
4. TITLE AND SUBTITLE Immunotherapy of Prostate Cancer With Genetically Enhanced Tumor-Specific T-Cell Precursors				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-09-1-0294	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. Marcel van den Brink E-Mail: vandenbm@mskcc.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Sloan-Kettering Institute for Cancer Research New York, NY 10021				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Precursor (Pre) T cells, when adoptively transferred further develop in the thymus into mature T cells, that is capable of lysing tumors. The overall objective of this project is to develop an effective 'off the shelf' adoptive cell therapy with PreT cells targeting prostate cancer. To enhance the anti-tumor activity of PreT cells we transduced these cells with a chimeric antigen receptor (CAR)-Pz1 targeting the prostate cancer associated antigen - prostate specific membrane antigen (PSMA). Here we show that prostate cancer specific PreT cells can be generated by expressing CARs targeting human PSMA. T cells derived from the adoptively transferred PreT cells develop in thymic and extrathymic sites and prolong survival of prostate cancer bearing recipients.					
15. SUBJECT TERMS prostate cancer, precursor T cells, adoptive transfer, prostate specific membrane antigen, chimeric antigen receptor					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	7	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	2
Body.....	2
Key Research Accomplishments.....	3
Reportable Outcomes.....	3
Conclusion.....	3
References.....	3
Supporting data.....	4

1. INTRODUCTION

Broader use of individual cell therapies are restricted by complex and expensive processes to manufacture a cell product that is limited to single patient use. The *goal of this project* is to extend the possibilities of curing malignant states using the immune system. *The overall objective of this application* is to develop an effective ‘off-the-shelf’ T cell precursor-based therapeutic strategy targeting prostate cancer. Based on studies in our and other laboratories we have *hypothesized* that genetically engineered T cell precursors (preT) expressing chimeric antigen receptors targeting prostate specific membrane antigen (PSMA) ¹ can be adoptively transferred to enhance tumor killing in prostate cancer-bearing recipients. We are developing an “off-the-shelf” prostate cancer cell therapy using preT cells with specific anti-PSMA activity, which can be administered after non-myeloablative conditioning and can engraft both in thymic and extrathymic sites without risk for graft-versus-host disease.

2. BODY

2.1 Development of hPSMA-specific T cell precursors.

T cell precursors can be engineered to stably express a chimeric antigen receptor (CAR) using viral vectors (Figure 1). The Pz1 expression lentiviral vector was designed in our collaborating laboratory led by Dr. Michel Sadelain. T cell precursors were developed *in vitro* from C57BL/6 BM-derived HSCs using the OP9-DL1 culture system. Viral vectors were produced by tripartite transfection of 293T cells with transfer genes (Pz1), pCMV Δ 8.92, and pUCMD.G⁵³ using 293 Transit (Mirus Bio). Vector supernatants were concentrated by ultra-centrifugation and 0.75-1.5 x 10⁸ total TU used to transduce 5 x 10⁵ T cell precursors (co-culture day 4–6) over 2 days in tissue culture plates coated with retronectin. Transduced cells were then expanded for an additional 14-21 days by OP9-DL1 co-culture. Transduction efficiencies of the T cell precursors were determined by flow cytometric analysis and were routinely in the range of 60% (Figure 2). FACS analysis of the co-cultured preT cells demonstrated primarily a double negative (DN) 2 and 3 stage characterized by CD4-CD8- CD44+/-CD25+.

2.2 Pz1+ preT cells home into thymic and extrathymic locations.

We adoptively transferred Pz1+ preT cells in B6→ B6 syngeneic bone marrow transplantation recipients (BMT) recipients. Pz1+ viral vector containing luciferase gene was used to track the transduced preT cells using *in vivo* imaging system (IVIS)². Weekly imaging of the transplanted mice demonstrated that the transduced Pz1+ preT cells traffic to the thymus for further development (Figure 3). Pz1+ preT cells are also seen to migrate to extrathymic sites. FACS analysis of the adoptively transferred mice showed mature Pz1+ T cells derived from adoptively transferred preT cells in host spleens (data not shown). Similar trafficking was also seen in control 19z1+ preT cells, indicating that the expression of the CAR Pz1 does not affect the trafficking and development of preT cells.

Further investigation revealed that preT cells engraft in extrathymic sites including gut and mesenteric lymph nodes. To study the development of extrathymic T cells from *ex vivo*-generated preT cells, we adoptively transferred preT cells in irradiated nude mice. Nude mice lack the *Foxn1* gene and do not have a functional thymus. We found that mature T cells derived from *ex vivo*-generated preT cells can be obtained in the absence of a functional thymus. These T cells can produce IFN γ and TNF α following stimulation. However, total body irradiation was critical to the engraftment and a single dose of 600cGy led to engraftment and T cell development (data not shown). We are currently exploring the development of T cells in aged mice, where the thymic function is known to decrease. These studies are relevant to patients of prostate cancer undergoing adoptive transfer of preT cells, who are usually of the older age group with a deficient thymic state.

2.3 Pz1+ preT cells can enhance survival of prostate cancer-bearing recipients.

We adoptively transferred Pz1+ preT cells in B6→ B6 syngeneic BMT recipients bearing hPSMA+RM1 tumor. Survival was monitored. Significantly enhanced survival of tumor-bearing mice was observed in the group treated with Pz1+ preT cells compared to those treated with control 19z1+ preT cells or the untreated group (Figure 4). Our results show that adoptive transfer of Pz1+ preT cells can immunologically target hPSMA-expressing cells and improve survival in tumor-bearing recipients. We are currently exploring the effect of third party Pz1+ preT cells in tumor-bearing hosts undergoing syngeneic BMT or non-myeloablative conditioning.

3. KEY RESEARCH ACCOMPLISHMENTS

1. We developed hPSMA-specific preT cells for adoptive transfer.
2. We demonstrated that Pz1+ preT cells undergo further development in the thymus and give rise to mature Pz1+ T cells.
3. Adoptively transfer of preT cells demonstrated that they also traffic to extrathymic sites and undergo further differentiation into mature T cells.
4. Adoptive transfer of Pz1+preT cells improved survival in prostate cancer-bearing recipients.

4. REPORTABLE OUTCOMES

-None-

5. CONCLUSION

In the present study, we extend our previous findings that Pz1+ preT cells can be generated for adoptive transfer. We also show that adoptively transferred Pz1+ preT undergo further differentiation in the thymus to give rise to Pz1+ mature CD4+ and CD8+ T cells. We also found that adoptively transferred preT cells can traffic to extrathymic locations to develop into functional mature T cells. We then adoptively transferred Pz1+ and control 19z+ preT cells into hPSMA+tumor-bearing recipients. Groups treated with Pz1+ preT cells had significantly better survival in tumor-bearing recipients.

Implications and outlook: Within the planned schedule, we have worked towards developing chimeric antigen receptor-expressing precursor T cells that can target prostate-specific membrane antigen-expressing tumor cells. Having proved the feasibility of this approach we will now adapt this approach using non-myeloablative conditioning regimens that we have developed over the last year. This would lead to the development of an “off-the-shelf” cell-based therapy without the requirement of bone marrow transplantation.

6. REFERENCES

1. Gade, T.P., *et al.* Targeted elimination of prostate cancer by genetically directed human T lymphocytes. *Cancer Res* **65**, 9080-9088 (2005).
2. Santos, E.B., *et al.* Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. *Nat Med* **15**, 338-344 (2009).

7. SUPPORTING DATA

Figure 1




Figure 1: Pz1 – Chimeric Antigen Receptor targeting human Prostate Specific Membrane Antigen

Figure 2




Figure 2: PreT cells primarily at the CD4-CD8-(DN) stage, expressing Pz1 gene, can be generated *ex vivo*. (Left panel) The co-cultured preT cells were stained with idio-specific antibody directed to the CAR, analyzed 7 days post transduction. (Right panels) The phenotype of transduced and expanded preT cells analyzed by FACS at day 21 of co-culture.

Figure 3




Figure 3: Pz1+ preT cells home into the thymic and extrathymic locations (A) (Pz1 or control 19z1)-luc+CAR+PreT + B6 BM → B6. In vivo imaging performed on day 14 post transplant.

Figure 4




Figure 4: Pz1+ PreT cells can enhance survival of prostate cancer bearing recipients.